FDA fast-tracks and approves Eli Lilly’s Foundayo (orforglipron), a daily oral GLP-1 pill for obesity

The FDA approved Eli Lilly's once-daily oral GLP-1 pill Foundayo (orforglipron) for chronic weight management in adults with obesity, completing its review in just 50 days after filing, the fastest approval of a new molecular entity since 2002. The drug reached patients the same day prescriptions opened via Lilly's direct-to-consumer platform LillyDirect, with broader retail and telehealth availability expected shortly after initial shipments begin April 6.

Foundayo is a GLP-1 receptor partial agonist in tablet form, taken orally once daily, starting at 0.8 mg and titrated upward over several months to a maximum dose of 17.2 mg based on tolerability. Crucially, it is the only GLP-1 pill for weight loss that can be taken any time of day without restrictions on food and water intake, a practical edge over the first-generation oral GLP-1 that required fasting. Acting CDER Director Tracy Beth Høeg cited that distinction explicitly in the FDA's announcement. Foundayo is also described as Lilly's second FDA-approved obesity medicine.

The clinical case rests primarily on ATTAIN-1, a Phase 3 global clinical development program that enrolled more than 4,500 people with obesity. In ATTAIN-1, patients on the highest dose who completed the trial lost an average of 27.3 pounds, or 12.4% of body weight, compared with 2.2 pounds on placebo. The trial also showed favorable changes in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure. Those numbers are meaningful but trail the weight-loss magnitude seen with Lilly's injectable Zepbound, a distinction that will shape how prescribers and payers position the drug.

The approval was completed under the FDA's Commissioner's National Priority Voucher pilot program, which enabled rolling review and enhanced communications between the agency and Eli Lilly. Commissioner Martin Makary framed the timeline as proof of concept: "This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners." The FDA said it will host a public meeting on June 4 to solicit broader feedback on the CNPV program's design and future eligibility criteria, signaling that this approval will itself become a policy test case.

Speed, however, compresses the observation window. Foundayo's labeling includes a boxed warning for thyroid C-cell tumors and carries warnings and precautions for pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, diabetic retinopathy in patients with type 2 diabetes, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. It should not be used in combination with another GLP-1 receptor agonist. That warning list mirrors the class profile for injectable GLP-1s, but post-market surveillance will be essential given how quickly the drug moved through pre-approval review.

Access will hinge on price and coverage. People with insurance coverage could pay $25 a month with a coupon from Lilly, while people paying out of pocket could pay between $149 and $349, depending on the dose. Eligible Medicare Part D patients may be able to access Foundayo starting July 1, 2026. Those tiers are lower than entry costs for injectable GLP-1s at launch, but whether pharmacy benefit managers match Lilly's coupon pricing with formulary placement remains unsettled. Employer health plans, which bore the brunt of Wegovy and Zepbound spending debates, will face immediate pressure to establish coverage criteria.

Orforglipron was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018, and as a small-molecule non-peptide compound it can be manufactured and distributed at a scale that peptide-based injectables cannot match, a supply argument CEO David Ricks has repeatedly invoked. Whether that manufacturing advantage translates into durable affordability, or simply into market share, is the unresolved question that will follow Foundayo through its first year on shelves.